If you've been taking a compounded GLP-1 medication — whether compounded semaglutide or compounded tirzepatide — and need to switch to an FDA-approved version, you're not alone. Since the FDA resolved the shortages for both tirzepatide (December 2024) and semaglutide (early 2025), the window for legal compounding has narrowed significantly, and thousands of patients have found themselves needing to make this transition.
Maybe your compounding pharmacy stopped filling your prescription. Maybe your telehealth provider pivoted to something else. Maybe you've been reading about dosing errors and salt form concerns and decided you want the consistency of an FDA-approved product.
Whatever brought you here, we can help you switch safely — whether you're moving to Wegovy, Zepbound, or another FDA-approved option.
Why Patients Are Switching
We see patients making this transition for several reasons:
The supply dried up. Now that the FDA has resolved the shortages for both semaglutide and tirzepatide, compounding these medications is only legal under very limited circumstances. Many compounding pharmacies have stopped producing them entirely. Telehealth companies that built their business on compounded GLP-1s have had to change their model or shut down.
Concerns about quality. The FDA has documented hundreds of adverse event reports linked to compounded GLP-1 medications, including hospitalizations from dosing errors. Some compounders used salt forms (semaglutide sodium, tirzepatide acetate) that haven't been tested for safety or effectiveness. For more context on this issue, read why PEAK does not prescribe compounded GLP-1 medications.
Insurance may now cover it. If you were paying cash for a compounded GLP-1 because insurance denied the brand-name version, it may be worth trying again. Coverage has expanded, and we handle prior authorizations aggressively.
You want the convenience. FDA-approved GLP-1 medications like Wegovy and Zepbound come in pre-filled pens with fixed doses. No measuring from a vial. No math. Click and inject.
How the Transition Works
Whether you're switching from compounded semaglutide to Wegovy (or Ozempic) or from compounded tirzepatide to Zepbound (or Mounjaro), the process follows the same general framework.
Step 1: Consultation and dose assessment
We'll review your current compounded dose, how long you've been taking it, and how you've responded. This helps us determine where to start you on the FDA-approved version.
Because compounded products vary in concentration, potency, and even chemical form, we can't assume your compounded dose is equivalent to the same number on a brand-name pen. We'll make a clinical judgment based on your history and response.
Step 2: Timing the switch
The standard approach is to wait 7 days after your last compounded injection before starting your FDA-approved medication. This is the same interval you'd normally wait between weekly doses.
If it's been more than 2 weeks since your last compounded injection, we'll treat you more like a new start and may begin at a lower dose to minimize side effects.
Compounded semaglutide to Wegovy
There's no official conversion chart from compounded semaglutide to Wegovy because compounded products aren't standardized. However, here's the general approach:
| Your compounded dose | Typical Wegovy starting point |
|---|---|
| 0.25 mg weekly | Wegovy 0.25 mg |
| 0.5 mg weekly | Wegovy 0.5 mg |
| 1.0 mg weekly | Wegovy 1.0 mg |
| 1.25-1.7 mg weekly | Wegovy 1.0 mg or 1.7 mg (clinical judgment) |
| 2.0+ mg weekly | Usually Wegovy 1.7 mg, then 2.4 mg |
Note: These are guidelines, not rules. Your provider will assess your individual situation.
Ozempic contains the same active ingredient as Wegovy (semaglutide) but is FDA-approved for type 2 diabetes, not weight loss. Its maximum dose is 2.0 mg vs. Wegovy's 2.4 mg. Your provider may prescribe Ozempic if clinically appropriate. Learn more about the difference.
Compounded tirzepatide to Zepbound
The conversion from compounded tirzepatide is generally more straightforward because the FDA-approved pen doses match the common compounded doses. However, compounded products may use different salt forms (tirzepatide acetate or sodium) that could affect how you respond.
| Your compounded dose | Typical Zepbound starting point |
|---|---|
| 2.5 mg weekly | Zepbound 2.5 mg |
| 5.0 mg weekly | Zepbound 5.0 mg |
| 7.5 mg weekly | Zepbound 7.5 mg |
| 10 mg weekly | Zepbound 10 mg |
| 12.5 mg weekly | Zepbound 12.5 mg |
| 15 mg weekly | Zepbound 15 mg |
Note: Even with matching dose numbers, your response may differ due to salt form variations in compounded products. Your provider will monitor and adjust.
Mounjaro contains the same active ingredient as Zepbound (tirzepatide) at identical doses but is FDA-approved for type 2 diabetes, not weight loss. Your provider may prescribe Mounjaro if clinically appropriate. Learn more about the difference.
What to Expect During the Transition
Will I feel different?
Most patients transitioning from a compounded GLP-1 to its FDA-approved equivalent at a comparable dose don't notice a major difference. The active ingredient is the same, and the mechanism is the same.
However, some patients report:
- More consistent appetite suppression (likely due to standardized dosing)
- Fewer injection site reactions
- Better tolerability (if their compounded product had quality issues)
If your compounded product used a salt form (semaglutide sodium, tirzepatide acetate, etc.), you might notice differences because you're now getting the FDA-approved base formulation.
Will I regain weight during the switch?
If you time the transition correctly (7 days between last compounded dose and first FDA-approved dose), there shouldn't be a significant gap in medication effect. These medications stay in your system for several days.
If there's a longer gap — say, because you ran out of compounded medication and it took time to get your FDA-approved prescription filled — you might notice some return of appetite. This is temporary. Once you're on your medication consistently, you'll be back on track.
Cost and Insurance
Step 3: Insurance and prior authorization
If you have insurance, we'll check your benefits and submit a prior authorization for Wegovy, Zepbound, or whichever FDA-approved medication your provider prescribes. Many commercial plans cover these medications, especially with documentation of:
- BMI criteria (30+ or 27+ with comorbidities)
- Previous weight loss attempts
- Medical necessity
Different medications have different PA requirements, and some insurers cover Wegovy but not Zepbound, or vice versa. We check your specific plan benefits and select the medication most likely to be covered. We submit PAs within 48 hours and handle appeals when needed.
Step 4: Ongoing monitoring
Once you're on your FDA-approved medication, we see you regularly — typically monthly during titration, then every 1-3 months at maintenance. This isn't a one-time prescription; it's ongoing medical care. Patients also frequently ask whether generic versions of these medications will eventually become available at a lower cost.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
